Cutaneous larva migrans is an itchy, migrating skin rash caused by animal hookworm larvae that accidentally burrow into human skin. It is common among travelers returning from tropical beaches, and it has a genuinely effective medical answer. This article sets out what cutaneous larva migrans actually is, why oral ivermectin has become the treatment most tropical medicine physicians reach for, what the clinical evidence actually shows and does not show, how the drug is dosed by body weight, and what a patient should realistically expect in the days and weeks after treatment.
What Cutaneous Larva Migrans Actually Is
The condition is caused mainly by Ancylostoma braziliense, a hookworm that normally lives in the intestines of dogs and cats, along with related species such as Ancylostoma caninum. Infected animals shed eggs in feces onto warm, sandy or moist soil. The eggs hatch into larvae that can penetrate bare human skin on contact — most often the feet, buttocks, or lower back of someone who has walked barefoot or lain on contaminated sand.
Humans are what parasitologists call a dead-end host: the larva cannot complete its life cycle in human tissue, so instead of settling down, it wanders aimlessly just beneath the skin's surface. This produces the classic sign of the disease — a raised, red, intensely itchy, thread-like track that advances a few millimeters to a couple of centimeters per day, tracing an irregular, serpentine line across the skin. Diagnosis is almost always made on the appearance of this track together with a history of recent barefoot beach exposure; no biopsy or blood test is usually needed.
Left alone, the larva eventually dies and the rash resolves on its own, but this can take several weeks to a few months, during which the itching is often severe enough to disturb sleep and scratching can introduce a secondary bacterial skin infection. That combination of prolonged discomfort and infection risk is why treatment is generally recommended rather than simply waiting it out.
Why Ivermectin Works Against the Parasite and Not Against the Patient
Ivermectin kills the larva by binding to glutamate-gated chloride channels concentrated in invertebrate nerve and muscle tissue. This binding causes an influx of chloride ions that paralyzes the parasite's muscles, and it dies. Mammals, including humans, do not rely on this same channel in the same way, and the drug has only weak affinity for the different chloride channels found in the mammalian central nervous system. On top of that, a pump called P-glycoprotein at the blood-brain barrier actively keeps most ivermectin out of the human brain. The net effect is a drug that is lethal to the parasite at doses that are, for almost all patients, very well tolerated.
It is worth pausing on where this molecule came from. Ivermectin is a derivative of avermectin, first isolated from Streptomyces avermitilis, a bacterium discovered in ordinary Japanese soil by microbiologist Satoshi Ōmura. William Campbell then developed its antiparasitic potential. Their work earned the 2015 Nobel Prize in Physiology or Medicine — a reminder that some of medicine's most useful tools have been sitting quietly in the created world, waiting to be found rather than invented.
The Clinical Evidence
The evidence for ivermectin in cutaneous larva migrans is not theoretical; it comes from actual patients treated and followed. A widely cited prospective study by Bouchaud and colleagues, published in Clinical Infectious Diseases in 2000, followed a group of travelers in France diagnosed with cutaneous larva migrans and treated with a single oral dose of ivermectin at roughly 200 micrograms per kilogram of body weight. Around three-quarters were cured with that single dose, and cure rates rose to near-total when a second dose was given about a week later to those who still had active lesions. A companion review by Caumes, published the same year in the same journal, pooled findings from several smaller trials and case series and reported cure rates generally in the 90-plus percent range with ivermectin, comparing favorably with older regimens.
Those older regimens are worth naming so readers understand the alternatives. Oral albendazole, typically given daily for three to seven days, is also effective, though it requires a longer course and is not always as reliably curative with a single dose. Topical thiabendazole or albendazole creams applied directly to the track can work but usually need a compounding pharmacy and repeated daily application over one to two weeks, which is far less convenient for a rash that is, by its nature, moving. Cryotherapy — freezing the visible track with liquid nitrogen — was used for decades but has fallen out of favor in current practice, because the larva is typically several millimeters ahead of the visible inflamed track, meaning the freezing often misses the parasite entirely while producing a painful blister. Modern reviews and tropical medicine references, including guidance used by travel clinics, do not recommend cryotherapy as first-line care.
One point deserves explicit statement: ivermectin is not FDA-approved specifically for cutaneous larva migrans. Its approved U.S. indications are strongyloidiasis and onchocerciasis. Its use for cutaneous larva migrans is off-label, though it is well supported in the tropical and travel medicine literature and is commonly used this way by physicians experienced in treating returning travelers. This is a normal and legitimate pattern in medicine — off-label use backed by trial data is different from use without evidence — but patients deserve to know the regulatory status plainly rather than assume otherwise.
Dosing in Practice
The standard adult dosing target is a single oral dose of approximately 200 micrograms per kilogram of body weight, taken with water as directed by the prescribing physician. Because ivermectin tablets in the United States are most commonly supplied as 3 mg tablets, the actual number of tablets a patient takes is calculated from their weight, not fixed at a single number for everyone. A person weighing around 50 to 65 kilograms, for example, often ends up taking a total dose in the neighborhood of 9 to 12 mg, which is why "12 mg" is a figure many patients see referenced — but it describes an average adult dose, not a universal one. Heavier or lighter patients need a different total, calculated properly.
- Dosing is weight-based and should be calculated by a physician or pharmacist, not estimated by the patient.
- A single dose is often curative; a second dose one to two weeks later is common if itching or track progression persists.
- Safety in children under about 15 kilograms has not been established, and alternative treatments are usually chosen for young children.
- Product should always come from a legitimate pharmacy dispensing the human pharmaceutical formulation at the correct strength — not veterinary products, which are formulated and concentrated differently and are not safe substitutes.
What to Expect After Treatment
Most patients notice the itching begin to ease within one to three days of treatment, as the larva is paralyzed and stops migrating. The visible track typically stops advancing within roughly forty-eight hours, though it does not vanish overnight — the inflamed skin along the dead larva's path needs one to two weeks to settle and heal, much like any healing irritation. If a track is still visibly extending after about a week, or new lesions appear, that is the signal to check back with a physician about a second dose rather than assuming the treatment failed outright, since this pattern is exactly what the Bouchaud study anticipated and addressed with a repeat dose.
Side effects from a single antiparasitic dose of ivermectin are generally mild when they occur at all — mild nausea, dizziness, or transient itching are the most commonly reported. Because scratching can break the skin, keep an eye out for increasing redness, warmth, swelling, or pus, which would suggest a secondary bacterial infection needing separate treatment, typically an antibiotic, rather than more antiparasitic medication.
Pregnant women and breastfeeding mothers, particularly of very young infants, should discuss timing and necessity with their physician rather than self-treating, since safety data in pregnancy is limited. This is a case where the right approach is not caution for its own sake but an honest conversation between patient and doctor about the specific situation, weighing the discomfort and infection risk of the untreated rash against what is and isn't known about the medication in pregnancy.
Prevention remains the most reliable protection, and it costs nothing but a little discipline: wear sandals or shoes on tropical beaches, use a towel or mat as a barrier rather than lying directly on sand, and be particularly cautious in areas frequented by stray or domestic dogs and cats. Families traveling with children do well to make this a simple habit rather than an afterthought — a small act of stewardship that avoids a much more uncomfortable few weeks.
Key takeaway: A single, correctly weight-dosed course of oral ivermectin, prescribed and supervised by a physician, is supported by real clinical trial evidence as a highly effective off-label treatment for cutaneous larva migrans, with itching typically easing within days and full skin healing within one to two weeks.